Singapore, July 24 -- GCCL, a South Korea-based leading provider of clinical trial sample analysis, and China & US based GemPharmatech, a global provider of in vivo efficacy testing and genetically engineered animal models, have announced the signing of a Memorandum of Understanding (MoU) to promote mutual collaboration in delivering integrated drug discovery and development services to pharmaceutical and biotechnology companies worldwide.

Under the terms of the MoU, GCCL and GemPharmatech will explore joint initiatives that combine GCCL's integrated clinical-stage central lab capabilities, including bioanalysis and sample management, with GemPharmatech's preclinical in vivo efficacy testing, disease models, and genetically engineered mo...